【摘要】 目的:研究固肾祛湿化浊汤与阿比特龙联合治疗去势抵抗性前列腺癌的临床疗效。方法:选取63例去势抵抗性前列腺癌(CRPC)患者纳入本次研究,采用随机数字表法将入选患者划分为对照组与治疗组,对照组给予阿比特龙治疗,治疗组在对照组疗法的同时给予固肾祛湿化浊汤治疗;治疗3个周期后,评估两组患者实体瘤临床疗效、中医症候积分与中医证候疗效,统计两组患者3个周期中不良反应发生情况,观察治疗前、后两组患者血清标志物:前列腺特异性抗原(PSA)、睾酮,尿流动力学指标:最大尿流率(MFR)、剩余尿量(PVR)与生活质量Karnofsky(KPS)评分的变化情况。结果:治疗组实体瘤整体临床疗效水平优于对照组(P<0.05);治疗组中医症候总有效率为96.43%,对照组为78.57%,治疗组中医证候总有效率与整体疗效水平均优于对照组(均P<0.05);治疗后两组中医症候积分均较治疗前降低(均P<0.05),且治疗组低于对照组(P<0.05);对照组不良反应发生率为35.71%,治疗组为21.43%,两组比较差异无统计学意义(P>0.05);治疗后,两组患者PSA、睾酮、PVR均较前下降(均P<0.05),MFR、KPS评分均较前升高(均P<0.05),且治疗组患者PSA、睾酮、PVR均低于对照组(均P<0.05),MFR、KPS评分均高于对照组(均P<0.05)。结论:固肾祛湿化浊汤与阿比特龙联合治疗去势抵抗性前列腺癌可提高临床疗效与生活质量,降低血清标志物表达水平,改善患者尿流动力学指标,且用药方案安全。更多还原

【Abstract】 Objective:To study the clinical efficacy and clinical indicators of the combination of Gushen Qushi Huazhuo decoction and abiraterone in the treatment of castration-resistant prostate cancer(CRPC).Methods:A total of 63 cases of CRPC patients were included in this study and divided into the control group and treatment group by using the random number table method.Patients in the control group were given abiraterone for treatment,while patients in the treatment group were give the Gushen Qushi Huazhuo decoction treatment on the basis of therapeutic method in the control group.After three treatment cycles,the clinical efficacy,traditional Chinese medicine(TCM) syndrome score and TCM syndrome effect of the two groups were evaluated in the two groups.The adverse reactions were analyzed within the three cycles of the two groups.Serum markers of prostate specific antigen(PSA) and testosterone,urine flow dynamic indexes of maximum urinary flow rate(MFR) and postvoid residual urine volume(PVR),and changes of Karnofsky performance score(KPS) were observed in patients of the two groups before and after treatment.Meanwhile,patients were followed up for at least 24 months to analyze the progression-free survival time(PFS) and overall survival(OS) time of the two groups.Results:The overall clinical efficacy of solid tumor in the treatment group was better than that in the control group(P<0.05).The total effective rate of TCM syndrome in the treatment group was 96.43%,while that in the control group was 78.57%.The total effective rate and overall efficacy of TCM syndrome in the treatment group were both better than that in the control group(all P<0.05).After treatment,the TCM syndrome scores of both groups were lower than that before treatment(all P<0.05),and the treatment group had a lower score than that of the control group(all P<0.05).The incidence of adverse reactions was 35.71% in the control group and 21.43% in the treatment group,and there was no statistical difference between the two groups(P>0.05).After treatment,PSA,testosterone and PVR of patients in both groups decreased compared with those before treatment(all P<0.05),while MFR and KPS scores increased than those before treatment(P<0.05).Besides,PSA,testosterone and PVR of patients in the treatment group were lower than those in the control group(all P<0.05),while MFR and KPS scores were higher than those in the control group(all P<0.05).Conclusion:The combination of Gushen Qushi Huazhuo decoction and abiraterone in the treatment of CRPC can improve the clinical efficacy and quality of life,reduce the expression level of serum markers,and improve the urodynamic parameters.更多还原